The Past, Present, and Future of Anti-IgE Therapy



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Immunoglobulin E is the last of the discovered immunoglobulins, which is the main mediator of allergic reactions. Its role in allergy pathogenesis led to the creation of the biological drug for the treatment of allergic diseases - omalizumab. Omalizumab binds free immunoglobulin E, preventing its binding to high-affinity receptors, thereby blocking the cascade of allergic inflammation. This review discusses the results of the main studies of omalizumab in the treatment of severe bronchial asthma, chronic spontaneous urticaria and other allergic diseases. Despite more than twenty years of use of the drug, its research is still ongoing. Thus, in 2024, omalizumab was approved for use in the prevention of anaphylaxis in patients with food allergies. The drug is being studied in combination with allergen-specific immunotherapy, as well as in patients with allergic bronchopulmonary aspergillosis.

Full Text

Restricted Access

About the authors

Natalia M. Nenasheva

Russian Medical Academy of Continuous Professional Education

Email: 1444031@gmail.com
ORCID iD: 0000-0002-3162-2510
SPIN-code: 3363-6170

MD, Dr. Sci. (Med.), Professor

Россия, 2/1 Barrikadnaya street, 125993 Moscow

Oksana M. Kurbacheva

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; ROSUNIMED

Email: kurbacheva@gmail.com
ORCID iD: 0000-0003-3250-0694
SPIN-code: 5698-6436

MD, Dr. Sci. (Medicine), Professor

Россия, Moscow; Moscow

Elena S. Fedenko

NRC Institute of Immunology FMBA of Russia

Author for correspondence.
Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087

MD, PhD, Doctor of Medical Sciences, professor

Россия

References

  1. Malveaux, F.J.; Conroy, M.C.; Adkinson, N.F.; Lichtenstein, L.M. IgE Receptors on Human Basophils. Relationship to Serum IgE Concentration. J. Clin. Investig. 1978, 62, 176–181.
  2. MacGlashan, D., Jr.; McKenzie-White, J.; Chichester, K.; Bochner, B.S.; Davis, F.M.; Schroeder, J.T.; Lichtenstein, L.M. In Vitro Regulation of FcεRIα Expression on Human Basophils by IgE Antibody. Blood 1998, 91, 1633–1643.
  3. Cruse, G.; Cockerill, S.; Bradding, P. IgE Alone Promotes Human Lung Mast Cell Survival through the Autocrine Production of IL-6. BMC Immunol. 2008, 9, 2. [CrossRef]
  4. Maurer, D.; Ebner, C.; Reininger, B.; Fiebiger, E.; Kraft, D.; Kinet, J.P.; Stingl, G. The High Affinity IgE Receptor (Fc Epsilon RI) Mediates IgE-Dependent Allergen Presentation. J. Immunol. 1995, 154, 6285–6290.
  5. 10. Holloway, J.A.; Holgate, S.T.; Semper, A.E. Expression of the High-Affinity IgE Receptor on Peripheral Blood Dendritic Cells: Differential Binding of IgE in Atopic Asthma. J. Allergy Clin. Immunol. 2001, 107, 1009–1018.
  6. Rajakulasingam, K.; Durham, S.R.; O’Brien, F.; Humbert, M.; Barata, L.T.; Reece, L.; Kay, A.B.; Grant, J.A. Enhanced Expression of High-Affinity IgE Receptor (Fc Epsilon RI) Alpha Chain in Human Allergen-Induced Rhinitis with Co-Localization to Mast Cells, Macrophages, Eosinophils, and Dendritic Cells. J. Allergy Clin. Immunol. 1997, 100, 78–86.
  7. Domingo, C. Omalizumab for Severe Asthma: Efficacy beyond the Atopic Patient? Drugs 2014, 74, 521–533.
  8. Palomares, Ó.; Sánchez-Ramón, S.; Dávila, I.; Prieto, L.; Pérez de Llano, L.; Lleonart, M.; Domingo, C.; Nieto, A. DIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. Int. J. Mol. Sci. 2017, 18, 1328.
  9. Chang, T.W. The Pharmacological Basis of Anti-IgE Therapy. Nat. Biotechnol. 2000, 18, 157–162.
  10. MacGlashan, D.W.; Bochner, B.S.; Adelman, D.C.; Jardieu, P.M.; Togias, A.; McKenzie-White, J.; Sterbinsky, S.A.; Hamilton, R.G.; Lichtenstein, L.M. Down-Regulation of Fc(Epsilon)RI Expression on Human Basophils during in Vivo Treatment of Atopic Patients with Anti-IgE Antibody. J. Immunol. 1997, 158, 1438–1445.
  11. Djukanovi´c, R.; Wilson, S.J.; Kraft, M.; Jarjour, N.N.; Steel, M.; Chung, K.F.; Bao, W.; Fowler-Taylor, A.; Matthews, J.; Busse, W.W.; et al. Effects of Treatment with Anti-Immunoglobulin E Antibody Omalizumab on Airway Inflammation in Allergic Asthma. Am. J. Respir. Crit. Care Med. 2004, 170, 583–593.
  12. Prussin, C.; Griffith, D.T.; Boesel, K.M.; Lin, H.; Foster, B.; Casale, T.B. Omalizumab Treatment Downregulates Dendritic Cell FcepsilonRI Expression. J. Allergy Clin. Immunol. 2003, 112, 1147–1154. [PubMed]
  13. Beck, L.A.; Marcotte, G.V.; MacGlashan, D.; Togias, A.; Saini, S. Omalizumab-Induced Reductions in Mast Cell Fce Psilon RI Expression and Function. J. Allergy Clin. Immunol. 2004, 114, 527–530.
  14. Lin, H.; Boesel, K.M.; Griffith, D.T.; Prussin, C.; Foster, B.; Romero, F.A.; Townley, R.; Casale, T.B. Omalizumab Rapidly Decreases Nasal Allergic Response and FcepsilonRI on Basophils. J. Allergy Clin. Immunol. 2004, 113, 297–302.
  15. Noga, O.; Hanf, G.; Kunkel, G. Immunological and Clinical Changes in Allergic Asthmatics Following Treatment with Omalizumab. Int. Arch. Allergy Immunol. 2003, 131, 46–52.
  16. Oliver, J.M.; Tarleton, C.A.; Gilmartin, L.; Archibeque, T.; Qualls, C.R.; Diehl, L.; Wilson, B.S.; Schuyler, M. Reduced FcεRIMediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab Therapy. Int.Arch. Allergy Immunol. 2009, 151, 275–284.
  17. Schroeder, J.T.; Bieneman, A.P.; Chichester, K.L.; Hamilton, R.G.; Xiao, H.; Saini, S.S.; Liu, M.C. Decreases in Human Dendritic Cell-Dependent T(H)2-like Responses after Acute in Vivo IgE Neutralization. J. Allergy Clin. Immunol. 2010, 125, 896–901.e6.
  18. Takaku, Y.; Soma, T.; Nishihara, F.; Nakagome, K.; Kobayashi, T.; Hagiwara, K.; Kanazawa, M.; Nagata, M. Omalizumab Attenuates Airway Inflammation and Interleukin-5 Production by Mononuclear Cells in Patients with Severe Allergic Asthma. Int. Arch. Allergy Immunol. 2013, 161 (Suppl. S2), 107–117.
  19. Humbert, M.; Beasley, R.; Ayres, J.; Slavin, R.; Hébert, J.; Bousquet, J.; Beeh, K.-M.; Ramos, S.; Canonica, G.W.; Hedgecock, S.; et al. Benefits of Omalizumab as Add-on Therapy in Patients with Severe Persistent Asthma Who Are Inadequately Controlled despite Best Available Therapy (GINA 2002 Step 4 Treatment): INNOVATE. Allergy 2005, 60, 309–316.
  20. Braunstahl, G.-J.; Chen, C.-W.; Maykut, R.; Georgiou, P.; Peachey, G.; Bruce, J. The EXpeRience Registry: The “real-World” Effectiveness of Omalizumab in Allergic Asthma. Respir. Med. 2013, 107, 1141–1151.
  21. Normansell, R.; Walker, S.; Milan, S.J.; Walters, E.H.; Nair, P. Omalizumab for Asthma in Adults and Children. Cochrane Database Syst. Rev. 2014, 1, CD003559.
  22. Siergiejko, Z.; ´Swiebocka, E.; Smith, N.; Peckitt, C.; Leo, J.; Peachey, G.; Maykut, R. Oral Corticosteroid Sparing with Omalizumab in Severe Allergic (IgE-Mediated) Asthma Patients. Curr. Med. Res. Opin. 2011, 27, 2223–2228.
  23. Domingo, C.; Moreno, A.; José Amengual, M.; Montón, C.; Suárez, D.; Pomares, X. Omalizumab in the Management of Oral Corticosteroid-Dependent IGE-Mediated Asthma Patients. Curr. Med. Res. Opin. 2011, 27, 45–53.
  24. Eisner, M.D.; Zazzali, J.L.; Miller, M.K.; Bradley, M.S.; Schatz, M. Longitudinal Changes in Asthma Control with Omalizumab: 2-Year Interim Data from the EXCELS Study. J. Asthma Off. J. Assoc. Care Asthma 2012, 49, 642–648.
  25. Chen, H.; Eisner, M.D.; Haselkorn, T.; Trzaskoma, B. Concomitant Asthma Medications in Moderate-to-Severe Allergic Asthma Treated with Omalizumab. Respir. Med. 2013, 107, 60–67.
  26. Papaioannou, A.I.; Mplizou, M.; Porpodis, K.; Fouka, E.; Zervas, E.; Samitas, K.; Markatos, M.; Bakakos, P.; Papiris, S.; Gaga, M.; et al. Long-Term Efficacy and Safety of Omalizumab in Patients with Allergic Asthma: A Real-Life Study. Allergy Asthma Proc. 2021, 42, 235–242.
  27. Namazy, J.A.; Blais, L.; Andrews, E.B.; Scheuerle, A.E.; Cabana, M.D.; Thorp, J.M.; Umetsu, D.T.; Veith, J.H.; Sun, D.; Kaufman, D.G.; et al. Pregnancy Outcomes in the Omalizumab Pregnancy Registry and a Disease-Matched Comparator Cohort. J. Allergy Clin. Immunol. 2020, 145, 528–536.e1.
  28. Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis (SOLAR). Allergy 2004; 59: 709–717.
  29. Yu C, Wang K, Cui X, et al. Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Am J Rhinol Allergy. 2020;34(2):196‐208.
  30. Павлова К.С., Куличенко Д.С., Курбачева О.М., Дынева М.Е., Ильина Н.И. Омализумаб в лечении сезонных обострений тяжёлого аллергического ринита // Российский Аллергологический Журнал. - 2022. - Т. 19. - №2. - C. 164-174. doi: 10.36691/RJA1539
  31. Metz M, Staubach P, Bauer A, et al. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcepsilonRI-positive cells in the skin. Theranostics. 2017;7(5):1266–76.
  32. Zhao ZT, Ji CM, Yu WJ, Meng L, Hawro T, Wei JF, Maurer M. Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials. J Allergy Clin Immunol. 2016 Jun;137(6):1742-1750.e4. doi: 10.1016/j.jaci.2015.12.1342.
  33. Tharp MD, Bernstein JA, Kavati A, Ortiz B, MacDonald K, Denhaerynck K, Abraham I, Lee CS. Benefits and Harms of Omalizumab Treatment in Adolescent and Adult Patients With Chronic Idiopathic (Spontaneous) Urticaria: A Meta-analysis of "Real-world" Evidence. JAMA Dermatol. 2019 Jan 1;155(1):29-38.
  34. Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Mar 7;390(10):889-899.
  35. Meiling Jin, Jo A. Douglass, J. Stuart Elborn et al. Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis. J Allergy Clin Immunol Pract 2023;11:896-905
  36. Wolfgang Pfützner and Mathias Schuppe. Use of biologics in allergen immunotherapy. Allergologie select, Vol. 5/2021 (108-118)

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © ABV-press,



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies